Erbitux

In the US, Erbitux (cetuximab systemic) is a member of the drug class EGFR inhibitors and is used to treat Colorectal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer and Squamous Cell Carcinoma.

US matches:

• Erbitux

UK matches:

• Erbitux 5mg/ml solution for infusion (SPC)

Ingredient matches for Erbitux

Cetuximab

Cetuximab is reported as an ingredient of Erbitux in the following countries:

• Argentina


• Australia


• Austria


• Bahrain


• Belgium


• Bulgaria


• Canada


• Chile


• China


• Colombia


• Croatia (Hrvatska)


• Czech Republic


• Denmark


• Egypt


• Finland


• France


• Germany


• Greece


• Hong Kong


• Hungary


• Iran


• Iraq


• Ireland


• Israel


• Italy


• Jordan


• Kuwait


• Lebanon


• Luxembourg


• Malaysia


• Mexico


• Netherlands


• New Zealand


• Norway


• Oman


• Peru


• Philippines


• Qatar


• Saudi Arabia


• Serbia


• Singapore


• Slovakia


• Slovenia


• South Africa


• Spain


• Sweden


• Switzerland


• Syria


• Taiwan


• United Arab Emirates


• United Kingdom


• United States


• Venezuela


• Yemen

International Drug Name Search

Glossary

SPC	Summary of Product Characteristics (UK)

Click for further information on drug naming conventions and International Nonproprietary Names.